ABSTRACT
To explore the effect of Naoshuming decoction on cerebral ischemic rats. Methods: The model of cerebral ischemia in rats was established via middle cerebral artery occlusion (MCAO). The MCAO model rats were randomly divided into a model group (n=36), a Naoshuming decoction at high dose group (n=36), a Naoshuming decoction at middle dose group (n=36) and a Naoshuming decoction at low dose group (n=36). In addition, a normal group (n=12) and a sham operation group (n=12) were included. Rats in each group were killed on the 3rd, 7th, and 14th day to detect relevant indicators. The Ayelet Levy 14 method was used to score the neurological function. Immunohistochemical method was used to detect the protein expression of nuclear factor kappa-B (NF-κB)/p50, NF-κB/p65, tumor necrosis factor-α (TNF-α), and IL-1β. The quantitative real-time PCR were used to detect the mRNA expression of NF-κB, TNF-α and IL-1β. Results: Compared with the sham group, at each time point, the inflammation indexes in the model group and different dose of Naoshuming decoction groups were significantly enhanced, and all of them showed neurological dysfunction. But the inflammatory indexes and neurological function scores would were gradually improved with the pass of time. Compared with the model group, the neurological dysfunction, the protein levels of NF-κB/p50, NF-κB/p65, TNF-α and IL-1β, and the mRNA of NF-κB, TNF-α and IL-1β in the high, middle and low dose of Naoshuming decoction groups were reduced at 3, 7 and 14 d, with statistical difference (all P<0.05 or P<0.01). Conclusion: Naoshuming decoction can alleviate the cerebral ischemic injury in rats.
Subject(s)
Animals , Rats , Brain Ischemia , Infarction, Middle Cerebral Artery , Inflammation , Interleukin-1beta , NF-kappa B , Tumor Necrosis Factor-alphaABSTRACT
Objective To observe the Clinical effects on Sanao tables combined with Montelukast Tables for cough variant asthma (CVA) (cold beam lung card).Methods Eighty-nine cases of sydrome differentiation (cold beam lung card) complied with CVA diagnostic criteria were randomly divided into treatment group (45 cases,3 cases were lost) and control group(44 cases,4 cases were lost)).The treatment group was given oral San'ao tables combined with Montelukast tables,and the control group was given oral Montelukast tables.The course of treatment were all 14 days.Chinese medical syndrome,cardinal symptom and airway reactivity effects were determined and compared at pretherapy.Results Clinical effects of Chinese medical syndrome (effective rate (90.48％,38/42),cough severity (85.71％,36/42),frequency (90.48％,38/42),cough up phlegm (85.71％,36/42),pharyngeal itching (80.95％,4/42) and aversion to cold (76.19％,32/ 42)) in treatment group were all superior to control group (70.00％ (28/40),62.50％ (25/40),70.00％ (28/ 40),55.00％ (22/40),52.50％ (21/40),25.00％ (10/40)).The differences were statistical significance (x2=14.046,14.046,13.923,23.104,17.729,17.729;P＜0.05 or P＜0.01).Conclusion Clinical effects of San' ao tables combined with Montelukast tables on CVA is superior to Montelukast tables.
ABSTRACT
Objective To observe the clinical efficacy of Shiwei Longdanhua Capsule combined with western medicine on patients with mild acute exacerbation of chronic obstructive pulmonary disease (COPD) with phlegm-heat obstructing lung syndrome. Methods Totally 192 cases of COPD with mild acute exacerbation (phlegm-heat obstructing lung syndrome) were recruited. They were randomly divided into the treatment group (96 cases) and the control group (96 cases). Patients in the control group were treated in line with the regular Western treatment, while patients in the treatment group were additionally treated by Shiwei Longdanhua Capsule. After 10-day treatment, the changes of TCM syndrome score, symptom integral and the lung function before and after treatment were compared. Results After treatment, 14 patients withdrew from the treatment group and 15 patients withdrew from the control group. The total efficiency rate of TCM syndrome was 80.49% (66/82) in the treatment group, while it was 56.79% (46/81) in the control group, with statistical difference between the two groups (P<0.05). The severity and frequency of cough and expectoration of the treatment group were better than the control group (P<0.05). The breathing symptom and pulmonary function of patients in the two groups improved, with similar efficacy. Conclusion The efficiency of Shiwei Longdanhua Capsule combined with Western medicine in the treatment of acute exacerbation of COPD is superior to that of simple Western medicine treatment, especially in terms of relieving cough and expectoration.
ABSTRACT
Professor XU Jian-zhong thought that the main pathologic mechanism of chronic obstructive pulmonary disease was phlegm,stasis,and deficiency.The treatment must aptly take action by integrated traditional and western medicine,integrated differential diagnosis of diseases and differentiation of symptoms and signs,integrated current medicine research production and TCM,so that the diseases can be cured.In acute stage,we should eliminate exogenous pathogen at first.Then,use clearing lung-heat and resolving phlegm,warming and resolving cold phlegm,dispersing the lung to stop coughing and relieve asthma.Yinqiao powder,dingchuan decoction,zhisou powder,Qian Jin weijing decoction,maxingshigan decoction,lingguizhugan decoction,wuling powder are the commonly used prescriptions.In paracmasia,replenishing qi,nourishing yin,consolidating the exterior,invigorating the spleen,reinforcing the kidney to improving the kidney,s function of receiving qi are the commonly used treatment methods,and yupingfeng powder、shengmai powder、xiangshaliujunzi decoction,qiweiduqi pills are the commonly used prescriptions.It is very helpful for critical patients to recover by aptly use mechanical ventilation.